Consumer Advocate Legal Update : Class Action Lawyers & Attorneys : Khorrami Pollard & Abir Law Firm : Mass Torts, Products Liability

Hormone treatment after menopause was originally studied by the Women’s Health Initiative (WHI) as part of a clinical trial established in 1992 to assess its relationship to coronary heart disease. Those studies were halted in 2002 when the results indicated that women taking a combination of estrogen and progestin had a higher risk of heart disease, stroke, and invasive breast cancer when compared to women taking a placebo. Now, a new study published October 20, 2010 in the Journal of the American Medical Association (JAMA) reports that these breast cancers associated with hormone treatment are more aggressive, more advanced, and have a higher mortality rate. 

The WHI continued to follow the women with breast cancer after the main trial had ended. Some earlier observational studies had suggested that hormone therapy induced breast cancers were less advanced and had a lower risk of death. However, this new WHI finding strongly contradicts those suggestions.   Combined hormone therapy increased the incidence of invasive breast cancer and in many cases the cancer had spread to the lymph nodes making it a more deadly form of cancer. Most significantly, it was found that the use of hormone therapy made the detection of breast cancer more difficult resulting in the cancer being diagnosed at a more advanced stage. 

For many years, menopausal women were treated with a combination of drugs to treat hot flashes and mood swings. Premarin, manufactured by Wyeth, contained estrogen, while Provera, manufactured by Pfizer’s Pharmacia and Upjohn, contained progestin.  In 1995, Wyeth combined the two hormones to form the medication, PremPro. Following the initial findings of the WHI in 2002 that linked estrogen and progestin to increased incidences of breast cancer, sales decreased dramatically. Sales of Premarin and PremPro were approximately $213 million in 2009, down from almost $2 billion prior to 2002. 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

On my way to work today I was listening to my usual talk radio show and a male caller called in asking about menopause. He basically wanted to learn more about it because his wife was going through it and he knew nothing about it except that it was a “medical condition”. This comment bothered me, not so much because I am a women and defensive about the topic, but because it mirrored the opinion of pharmaceutical companies, that for years made a fortune on hormone therapy drugs convincing people of just that…….that menopause was a condition that must be treated.

Recent articles in the New York Times and Huffington Post paint the picture of how Wyeth lured women into taking their hormone drugs, not only to retain their femininity, but to prevent heart disease, Alzheimer’s and dementia. Feel like a woman while warding off evil ailments, what woman would say no to that? They turned menopause into a disease that had to be treated. Women who every month would curse the day their menstrual cycle began were now dreading the day that it would end.

I must say Wyeth did a good job creating and spreading their image of menopause. Hopefully, the negative image will be replaced with what menopause really is…….a natural biological process, nothing more, nothing less. Until then, I guess I will just wait for my impending “medical condition” to kick in.
 

• Email This
• Print
• Comments
• Trackbacks
• Share Link

KPA Moves Forward in Complex Litigation on Behalf of Women with Breast Cancer Linked to Premarin and Prempro

Two multi-million dollar verdicts in Philadelphia last week against pharmaceutical company Wyeth, a division of Pfizer, reinforce that juries are consistently finding the company responsible for breast cancer in women who took its Premarin and Prempro hormone replacement therapy (HRT) drugs.

And just last month, a ruling from the 8th Circuit Court of Appeals confirmed that Wyeth did wrong, and that juries should be permitted to hear this evidence and determine whether the company should be punished.

In the verdicts announced last week, juries awarded Donna Kendall of Decatur, Illinois $6.3 million in compensatory and $28 million in punitive damages, and Connie Barton of Peoria, Illinois $3.7 million in compensatory and $75 million in punitive damages.

Through an ongoing federal multi-district litigation mass tort action, Wyeth still faces lawsuits from more than 10,000 women nationwide who claim that the company’s drugs caused their breast cancer. Of the 12 verdicts announced to date, plaintiffs have been awarded money in 10 of the cases. Every jury that has been permitted to deliberate on punitive damages has returned substantial awards.

To date, winning plaintiffs have been awarded a total of more than $42 million in compensatory and $165 million in punitive damages. In addition, 13 women have settled their HRT claims with Wyeth or Pfizer outside of court.

Shawn Khorrami, founding partner of KPA, is a member of the Plaintiffs’ Steering Committee for the MDL litigation team, and his firm represents around 150 individuals pursuing cases against Wyeth.

A press release on the firm’s involvement with the litigation was released today. For more information on the Barton and Kendall verdicts watch the video below.
 

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link